The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
Hsiang-Chun LeeYi-Lin ShiouShih-Jie JhuoChia-Yuan ChangPo-Len LiuWun-Jyun JhuangZen-Kong DaiWei-Yu ChenYun-Fang ChenAn-Sheng LeePublished in: Cardiovascular diabetology (2019)
Empagliflozin improves hemodynamics in our hypertensive heart failure rat model, associated with renal protection, attenuated cardiac fibrosis, and normalization of HF genes. Our results contribute some understanding of the pleiotropic effects of empagliflozin on improving heart function.